Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization.

Naina HV, Pruthi RK, Inwards DJ, Dingli D, Litzow MR, Ansell SM, William HJ, Dispenzieri A, Buadi FK, Elliott MA, Gastineau DA, Gertz MA, Hayman SR, Johnston PB, Lacy MQ, Micallef IN, Porrata LF, Kumar S.

Bone Marrow Transplant. 2011 Feb;46(2):291-3. doi: 10.1038/bmt.2010.106. Epub 2010 May 3.

PMID:
20436522
2.

Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation.

Gonsalves A, Carrier M, Wells PS, McDiarmid SA, Huebsch LB, Allan DS.

J Thromb Haemost. 2008 Sep;6(9):1468-73. doi: 10.1111/j.1538-7836.2008.03077.x. Epub 2008 Jul 8.

3.

Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.

Bellido M, Sureda A, Martino R, Madoz P, García J, Brunet S.

Haematologica. 1998 May;83(5):428-31.

4.

Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease.

Rosenbaum C, Peace D, Rich E, Van Besien K.

Biol Blood Marrow Transplant. 2008 Jun;14(6):719-23. doi: 10.1016/j.bbmt.2008.03.001.

5.

Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients.

Kolbe K, Peschel C, Rupilius B, Després D, Burger K, Sklenar I, Färber L, Huber C, Derigs HG.

Bone Marrow Transplant. 1997 Dec;20(12):1027-32.

6.

Incidence and risk factors of venous thromboembolic events in lymphoma.

Zhou X, Teegala S, Huen A, Ji Y, Fayad L, Hagemeister FB, Gladish G, Vadhan-Raj S.

Am J Med. 2010 Oct;123(10):935-41. doi: 10.1016/j.amjmed.2010.05.021.

PMID:
20920696
7.

A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma.

Takeyama K, Ogura M, Morishima Y, Kasai M, Kiyama Y, Ohnishi K, Mitsuya H, Kawano F, Masaki Y, Sasaki T, Chou T, Yokozawa T, Tobinai K; Lenograstim/Lymphoma Study Group.

Jpn J Clin Oncol. 2003 Feb;33(2):78-85.

PMID:
12629058
8.
9.

The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention.

Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB.

Blood. 2008 Aug 1;112(3):504-10. doi: 10.1182/blood-2007-10-117051. Epub 2008 May 14.

10.

A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.

Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K, DiPersio J.

Biol Blood Marrow Transplant. 2008 Nov;14(11):1253-61. doi: 10.1016/j.bbmt.2008.08.011.

11.

Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice.

Vantelon JM, Koscielny S, Brault P, Bourhis JH, Ribrag V, Pico J, Fenaux P, Munck JN.

Bone Marrow Transplant. 2000 Mar;25(5):495-9.

12.

Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.

Micallef IN, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Bridger G, Calandra G.

Biol Blood Marrow Transplant. 2009 Dec;15(12):1578-86. doi: 10.1016/j.bbmt.2009.08.005. Epub 2009 Oct 4.

14.

Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.

Reeves D, Liu CY.

J Oncol Pharm Pract. 2010 Mar;16(1):27-31. doi: 10.1177/1078155209104379. Epub 2009 Apr 28.

PMID:
19401307
15.

Venous thromboembolism in ANCA-associated vasculitis--incidence and risk factors.

Stassen PM, Derks RP, Kallenberg CG, Stegeman CA.

Rheumatology (Oxford). 2008 Apr;47(4):530-4. doi: 10.1093/rheumatology/ken035.

PMID:
18356178
16.

Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.

Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.

Bone Marrow Transplant. 1999 Feb;23(3):235-41.

17.

Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients.

Lefrère F, Bernard M, Audat F, Cavazzana-Calvo M, Belanger C, Hermine O, Arnulf B, Buzyn A, Varet B.

Leuk Lymphoma. 1999 Nov;35(5-6):501-5.

PMID:
10609787
18.

Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: a pilot study.

Lu JP, Knudson MM, Bir N, Kallet R, Atkinson K.

J Am Coll Surg. 2009 Nov;209(5):589-94. doi: 10.1016/j.jamcollsurg.2009.08.001. Epub 2009 Sep 11.

PMID:
19854398
19.

Peripheral blood stem cell mobilization with chemotherapy and granulocyte-colony stimulating factor in patients with hematological malignancies.

Watanabe S, Mukaiyama T, Ogawa Y, Kawada H, Ichikawa Y.

Tokai J Exp Clin Med. 1994 Dec;19(3-6):143-55.

PMID:
7570686
20.

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G; 3101 Investigators.

J Clin Oncol. 2009 Oct 1;27(28):4767-73. doi: 10.1200/JCO.2008.20.7209. Epub 2009 Aug 31.

PMID:
19720922

Supplemental Content

Support Center